HealthCore Evolution Drives Better Data Alignment for Customers    WILMINGTON, Del. — Feb. 2, 2021 — Mark Cziraky, former vice president of scientific affairs, chief growth officer, and co-founder of HealthCore, Inc. has become president of HealthCore while Marcus Wilson, former president and co-founder, now leads the Enterprise Analytics Hub, a new division of Anthem, […]

HealthCore Coordinating First US Longitudinal Study to Understand New COVID-19 Pediatric Syndrome With Greater Impact on Black and Latino Children November 16, 2020 09:00 AM Eastern Standard Time WILMINGTON, Del.–(BUSINESS WIRE)–HealthCore, an outcomes research company of Anthem, Inc., is managing a new study to help understand and combat the pediatric public health emergency arising from […]

THE NEWS JOURNAL NAMES HEALTHCORE A WINNER OF THE DELAWARE TOP WORKPLACES 2020 AWARD WILMINGTON, Del., Aug. 24, 2020 – HealthCore, Inc. has been awarded a Top Workplaces 2020 honor by The News Journal. The list is based solely on employee feedback gathered through an anonymous third-party survey that measures 15 drivers of engaged cultures […]

Accompanying editorial calls for further refinements in value-based insurance design to reduce unintended use of low-value care, reports the latest issue of The American Journal of Managed Care®. May 14, 2019 10:40 AM Eastern Daylight Time CRANBURY, N.J.–(BUSINESS WIRE)–When a large national employer removed cost sharing for primary care visits, medical utilization fell, as did […]

January 23, 2019 – At more than $54 billion, spending to treat all orthopedic pain conditions (including pain in the muscles, bones and joints) represents more than 14 percent of overall healthcare spending for commercially insured adult Blue Cross Blue Shield (BCBS) members.1,2 This report identifies trends in cost and quality of care for elective […]

Real-world study compares Ozempic® (semaglutide) to other standard diabetes therapies October 17, 2018 09:00 AM Eastern Daylight Time WILMINGTON, Del.–(BUSINESS WIRE)–HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. (NYSE: ANTM) and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind […]